Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

What Was Tested

Researchers studied Cagrilintide and Semaglutide in this randomized controlled trial publication.

The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Cagrilintide and who got the comparison, which limits bias.

As a double-blind Cagrilintide study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Cagrilintide, giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

REIMAGINE 2 was a randomised, double-blind, placebo-controlled and active-controlled, parallel-group study conducted in 30 countries (trial sites included university hospitals, health-care centres, research centres, and other centres).

This study is registered with ClinicalTrials.gov (NCT06065540) and is complete.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Semaglutide, Glucagon-Like Peptides, Hypoglycemic Agents, Blood Glucose, Glycated Hemoglobin and Drug Combinations.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cagrilintide and Semaglutide.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Cagrilintide compound page and the Semaglutide compound page, all human trials.